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ABSTRACT
Objectives: The outcome of patients with primary melanoma 
(PM) cannot be completely explained based on currently 
adopted clinical-histopathologic criteria. In this study, we 
evaluated the potential prognostic value of mismatch repair 
protein expression in PMs.
Methods: We examined the immunohistochemical staining 
of mismatch repair proteins in 18 benign nevi and 101 stage 
I to III PMs and investigated their association with tumor 
clinicopathologic variables and melanoma mortality.
Results: Expression of MSH2, MLH1, and PMS2 was 
high in benign nevi and reduced in a subset of PMs. 
Conversely, MSH6 expression was absent or extremely 
low in benign nevi and increased in a subset of PMs. In 
the multivariate analysis, including sex, age, Breslow 
thickness, and ulceration, high MSH6 expression in PMs (ie, 
immunostaining in >20% of tumor cells) was significantly 
associated with an increased risk of melanoma mortality 
(relative risk, 3.76; 95% confidence interval, 1.12-12.70).
Conclusions: MSH6 protein expression can be a valuable 
marker to improve prognosis assessment in PMs.
Cutaneous melanoma is an extremely aggressive 
malignant disease, endowed with high metastatic potential 
and affecting predominantly young people. Moreover, with the 
exception of lung cancer in women, its worldwide incidence 
is increasing faster than that of any other neoplastic disease.1,2
Presently, the prognosis of a patient with cutaneous mela-
noma is essentially derived from clinical and histopathologic 
parameters. The dominant prognostic factors for patients with 
localized or regional metastatic melanoma are represented 
by primary tumor thickness, ulceration, number of mitoses/
mm2 (for tumors ≤1.0 mm), and the number of tumor-positive 
nodes and their tumor burden.3 All these parameters are incor-
porated in the latest version of the American Joint Committee 
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on Cancer (AJCC) staging system for melanoma.3 According 
to survival data from the AJCC melanoma database, the prob-
ability of 5-year survival for patients with localized stage I 
melanoma is higher than 90%, whereas that for patients with 
stage II disease ranges between 45% and 77%.3 Once metas-
tasis to regional lymph nodes occurs (stage III), the 5-year 
survival ranges from 24% to 69%.3 However, due to the high 
biological heterogeneity of melanoma, an individual patient’s 
prognosis cannot be accurately predicted by the currently 
adopted clinical-histopathologic criteria, and therefore there 
is a pressing need to identify new molecular markers that may 
aid risk stratification of patients with stage I to III melanoma 
and hence improve selection of those patients to be enrolled 
for adjuvant therapy.4,5
During the past decade, high-throughput technologies 
evaluating expression levels of protein-coding genes have 
been used extensively in cancer research to uncover critical 
molecular events underlying disease development and 
progression, as well as to identify new potential prognostic 
markers and therapeutic targets. In this regard, several studies 
have been performed on melanoma cell lines or specimens 
to identify gene expression signatures associated with tumor 
cell metastatic potential (ie, invasiveness signatures), patient 
disease-free survival, and/or overall survival (ie, prognostic 
signatures).6-7 These investigations, as a consequence of 
their heterogeneity in terms of sample (ie, cell lines, primary 
melanoma, or metastases) and study population, as well 
as array platforms and biostatistical methods used, have 
generated a number of different prognostic or invasiveness 
signatures containing a limited number of overlapping 
genes.6,7 Nevertheless, when biological processes are 
considered, most of the identified signatures show that genes 
differentially expressed between invasive and noninvasive 
melanomas or associated with distinct clinical outcomes 
are mainly involved in the regulation of apoptosis, cell 
cycle progression, DNA duplication and repair, epithelial-
mesenchymal transition, and immune response.6,7 In 
particular, elevated levels of DNA repair gene transcripts, 
including those of several genes participating in mismatch 
repair (MMR), have been associated with unfavorable 
histopathologic features and/or poor clinical outcome in four 
of the seven studies performed on primary melanomas to 
identify prognostic gene signatures.8-14
Although gene expression profiling has provided useful 
insight into the molecular mechanisms involved in melanoma 
development and progression and most likely will improve 
disease management in the era of personalized medicine, it 
is not yet practicable for the routine prognostic assessment 
of patients with melanoma. On the other hand, immunohis-
tochemistry can be equally informative in characterizing the 
expression pattern of specific proteins in formalin-fixed, par-
affin-embedded tumor specimens while preserving tissue and 
cellular architecture. Confirmation of gene expression profil-
ing data at the protein level using immunohistochemistry and 
assessment of protein expression association with patient 
outcome could be therefore a valuable strategy to identify 
new potential prognostic markers. On these bases, in the pres-
ent investigation, we evaluated the expression of the four key 
proteins involved in MMR—namely, MSH2, MSH6, MLH1, 
and PMS215,16—in both benign nevi and a large series of 
stage I to III primary melanomas. Thereafter, we investigated 
the association between protein expression in the malignant 
lesions and clinicopathologic variables and 10-year melanoma 
mortality. Actually, elevated levels of MSH2 and/or MSH6 
messenger RNA (mRNA) have been detected in primary 
melanomas with poor prognosis by different studies.8,10,12,13
Materials and Methods
Patients and Specimens
The study, a hospital-based retrospective cohort study, 
was conducted on 101 patients who underwent surgical 
resection of a sporadic primary cutaneous melanoma at the 
Istituto Dermopatico dell’Immacolata-IRCCS (IDI) from 
January 1995 through December 2001. The study also 
included 18 patients who underwent surgical resection of a 
compound melanocytic nevus (CMN). These patients were 
selected to be comparable to the group of patients with 
melanoma in terms of the percentage of males and females as 
well as in terms of age range. Characteristics of all patients 
and primary melanomas are shown in ❚Table 1❚. The study 
was conducted according to the Declaration of Helsinki 
principles and approved by the Ethical Committee of the IDI 
(No. 148/CE/2011; December 16, 2011). Written informed 
consent was obtained from all patients.
Archival H&E-stained sections of all lesions were 
reexamined by one pathologist (F.P.), and the following 
histologic features were recorded for the melanoma specimens: 
(1) histologic type, (2) Breslow thickness, (3) mitotic rate (ie, 
number of mitoses/mm2), and (4) presence or absence of 
regression or ulceration. The presence of an increased number 
of blood vessels or scattered lymphocytes and melanin-laden 
macrophages together with lamella fibrosis in the dermis 
close to the tumor was recorded as a sign of regression.17 
Ulceration was considered present if there was full-thickness 
loss of the epidermis.
Seven clinical parameters were included in the database 
used to conduct the study: age, sex, location of primary 
melanoma, date of diagnosis, clinical stage at the date of 
diagnosis, cause, and date of death. Anatomical location 
of the primary tumor was categorized as trunk, head/neck, 
upper extremities, or lower extremities. Clinical stage of all 
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patients with melanoma at the time of diagnosis was reeval-
uated based on hospital clinical records and primary tumor 
histopathologic features and determined according to the 2009 
AJCC Melanoma Staging and Classification.3
Immunohistochemistry
The immunohistochemical analysis of MMR protein 
expression was performed on deparaffinized tissue sections by 
using the monoclonal antibodies and the indirect peroxidase 
method previously described,18 except that incubation with 
the anti-MSH6 antibody was performed at 4°C for 24 hours 
instead of at room temperature for 2 hours. Normal and 
neoplastic cells with nuclear immunohistochemical expression 
of MMR proteins were considered positive cells. Keratinocyte 
positivity18-20 was used as adequate internal positive control 
for each case to validate technical procedures. For each 
biopsy specimen, the total number of negative or positive 
nevus cells or melanoma cells was counted in at least five 
different high-power fields. The results were pooled and the 
percentage of positive nevus cells or melanoma cells was 
calculated. Moreover, slides were evaluated independently by 
two blinded observers (F.P. and A.M.), and the final average of 
the percentages of positive cells given by the two pathologists 
was calculated. A good agreement was obtained between the 
two individual investigators with respect to the percentage 
of cells scored as positive. In a few cases, the percentages 
varied. These slides were reexamined by both pathologists 
and a consensus was obtained. Melanoma cases were divided 
into 10 classes based on the percentage of stained tumor cells 
(first class, 0%-10% positive cells; 10% increment for the 
subsequent classes).
Patients’ Vital Status
Files from the Registry Office of the Lazio Region were 
examined to obtain information on vital status and cause-
specific death of patients. The International Classification 
of Diseases, Ninth Revision, was used to classify death due 
to cancer (codes 172.0-172.9). The length of follow-up for 
each patient was calculated as the number of days from the 
diagnosis of primary melanoma to the date of death or to the 
end of the follow-up. Patients who were alive or had died of 
other causes were considered censored.
Statistical Analysis
Groups were compared with the Pearson c2 test or Fisher 
exact test for categorical variables and with the Kruskal-Wallis 
test for continuous variables. The Kaplan-Meier method was 
used to calculate melanoma survival (MS) by patient baseline 
characteristics and by levels of tumor thickness, histologic type, 
site of tumor, presence of ulceration, regression, mitotic rate, 
and MMR protein expression, with statistical P values generated 
by the Cox-Mantel log rank test. We assessed the potential for 
violation of the proportional hazards assumption by comparing 
the survival curves for each level of a variable. The multivariate 
Cox proportional hazards model was used to test for the 
independent relationship between MSH6 protein expression and 
melanoma mortality. Demographic and clinicopathologic factors 
were considered possible confounding factors. For analysis 
purposes, MMR protein expression levels were dichotomized 
based on percentiles of the distribution. Statistical significance 
was set at P < .05. Data were analyzed with STATA software 
(Stata 11.0; StataCorp LP, College Station, TX).
❚Table 1❚
Patients’ Demographic and Clinicopathologic Data
Characteristic No. (%)
Patients with melanoma (n = 101) 
   Sex 
      Male 58 (57.4)
      Female 43 (42.6)
   Age, y  
      ≤49 39 (38.6)
      50-64 33 (32.7)
      ≥65 29 (28.7)
   Breslow thickness, mm 
      ≤1.00 33 (32.6)
      1.01-2.00 24 (23.8)
      2.01-4.00 20 (19.8)
      >4.00 24 (23.8)
   Anatomical site 
      Head/neck 13 (12.9)
      Trunk 37 (36.6)
      Upper limb 22 (21.8)
      Lower limb 29 (28.7)
   Histologic type 
      Superficial spreading 62 (61.4)
      Nodular 39 (28.6)
   Ulceration 
      Absent 87 (86.1)
      Present 14 (13.9)
   Regression 
      Absent 93 (92.1)
      Present 8 (7.9)
   Mitoses/mm2 
      <1 42 (41.6)
      ≥1 58 (57.4)
      NE 1 (1.0)
      Growth phase 
      Radial 9 (8.9)
      Vertical 92 (91.1)
   AJCC clinical stage 
      IA, IB 57 (56.4)
      IIA, IIB, IIC 39 (38.6)
      III 4 (4.0)
      NA 1 (1.0)
Patients diagnosed with CMN (n = 18) 
   Sex 
      Male 9 (50.0)
      Female 9 (50.0)
   Age, y 
      ≤49 7 (38.9)
      50-64 6 (33.3)
        ≥65 5 (27.8)
AJCC, American Joint Committee on Cancer; CMN, compound melanocytic nevus; 
NA, not available; NE, not evaluable.
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were equally expressed. Among the samples included in the 
lowest expression class (ie, 0%-10%), six were negative. 
Representative images of MMR protein expression in primary 
melanomas are illustrated in Image 1.
Association Between MMR Protein Expression and 
Demographic and Clinicopathologic Variables
The χ2 or Fisher exact test was used to study the 
association between the expression of each MMR protein and 
clinicopathologic variables. MMR protein expression levels 
were dichotomized based on percentiles of the distribution. 
Briefly, MSH2, MLH1, and PMS2 expression in primary 
melanomas was recorded as high when the percentage of 
positive tumor cells was more than 80% and as low when it 
was 80% or less. MSH6 expression was considered high when 
the percentage of positive tumor cells was more than 20% and 
low when it was 20% or less.
A statistically significant association was observed 
between MSH6 expression and Breslow thickness, ulceration, 
mitotic rate, and clinical stage ❚Table 3❚. High MSH6 
expression was found mainly in melanomas with a Breslow 
thickness of more than 2 mm (63.9%) compared with 
melanomas with a Breslow thickness of 2 mm or less (36.1%) 
(P = .002). Ulceration was present in 22.2% of melanomas 
with high MSH6 expression (H-MSH6 melanomas) and 
in only 6.6% of melanomas with low MSH6 expression 
(L-MSH6 melanomas) (P = .05). High mitotic rate (ie, 
mitoses/mm2 ≥1) was also more frequent among H-MSH6 
melanomas (77.8%) in comparison with L-MSH6 melanomas 
(P = .003). High MSH6 expression was also associated with 
AJCC clinical stages II to III (P = .003). No significant 
associations were observed between the expression of MSH2, 
MLH1, PMS2, and clinicopathologic variables.
Melanoma Survival
Seventy-seven of the 101 patients with melanoma 
included in the study were residents in the Lazio Region 
and had complete information on vital status. During the 
observation period, 19 deaths occurred, 13 of which were 
due to melanoma. The median follow-up time was 9.3 years 
(range, 8.3 months to 10.9 years).
❚Table 4❚ shows the 10-year MS according to 
demographic and clinicopathologic variables. Patients with 
nodular melanoma had lower MS compared with patients 
with superficial spreading melanoma (70.2% vs 89.4%, P 
= .01). Significantly lower survival was also observed for 
patients whose tumor had a Breslow thickness of more than 
4 mm or mitoses/mm2 of 1 or more compared with patients 
whose tumor had a Breslow thickness of 4 mm or less or 
mitoses/mm2 of less than 1 (50.5% vs 91.4%, P < .0001, and 
63.3% vs 100%, P < .001, respectively). In addition, MS was 
significantly lower in patients with stage II to III disease than 
Results
Expression of MMR Proteins in CMNs and Primary 
Melanomas
Immunohistochemical analysis of MSH2, MSH6, MLH1, 
and PMS2 protein expression was carried out on 18 specimens 
of CMN and on the primary tumors of 101 patients with stage 
I to III melanoma.
In all CMNs, nuclear immunostaining for MSH2, MLH1, 
and PMS2 was detected in more than 90% of the melanocytic 
population  ❚Image 1❚ (and data not shown). On the other 
hand, immunoreactivity for MSH6 was either absent or 
detectable in a few nevus cells at the dermal-epidermal 
junction (Image 1 and data not shown). In agreement with 
previous findings,18-20 positive staining for the four proteins 
was detected in normal epidermis present in the sections of 
CMNs. Nuclear immunoreactivity for all the MMR proteins 
was found in epidermal keratinocytes predominantly in the 
basal and first one to three suprabasal cell layers. Single 
scattered cells positive for MSH2, MLH1, and PMS2 were also 
detected in the uppermost epidermal layers (Image 1). Dermal 
fibroblasts, as well as endothelial cells of dermal vessels and 
pericytes or smooth muscle cells in the microvascular wall, 
showed either no or only weak immunoreactivity for the 
MMR proteins (data not shown).
Expression of the four MMR proteins in primary 
melanomas was initially categorized into 10 classes based 
on the percentage of positive tumor cells. The number of 
tumor samples within each class is illustrated in ❚Table 2❚. 
Among the 101 primary melanomas, 68 (67.3%) and 77 
(76.2%) samples showed positive immunostaining for MLH1 
and PMS2, respectively, in more than 80% of the tumor 
cells. Most of the remaining cases displayed MLH1 and 
PMS2 immunostaining in 71% to 80% of the tumor cells, 
whereas only a limited number of biopsy specimens showed 
immunoreactivity in 70% or less of the melanoma cells. 
MSH2 expression showed a more heterogeneous pattern. 
Indeed, 38 (38.4%) tumor samples showed a percentage of 
positive tumor cells higher than 80%, 29 (29.3%) specimens 
displayed immunostaining in 71% to 80% of the tumor cells, 
and 32 (32.3%) melanomas showed a percentage of positive 
tumor cells of 70% or less. None of the cases was negative 
for MSH2. A different pattern of distribution was observed 
for MSH6, with 62.8% of the melanomas showing positive 
immunostaining in 20% or less of the tumor cells and most 
of the remaining cases displaying a percentage of positive 
tumor cells between 21% and 60%. In each MSH6-positive 
melanoma, the percentage of cells staining positive for MSH6 
was lower than that of cells staining positive for MLH1 and 
PMS2, as well as lower than that of MSH2-positive cells, 
with the exception of three cases in which MSH6 and MSH2 
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❚Image 1❚ Representative images of MSH2 (A), MSH6 (B), MLH1 (C), and PMS2 (D) expression in compound melanocytic nevi 
(Pt13) and of MSH6 expression in primary melanomas (Pt5 and Pt79). E, Pt5, positive immunostaining for MSH6 protein in 45% 
of tumor cells. F, Pt79, positive immunostaining for MSH6 protein in less than 10% of tumor cells. Immunostaining of mismatch 
repair proteins was performed by the indirect peroxidase method. Sections were lightly counterstained with hematoxylin (×100). 
Pt, patient.
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❚Table 2❚
Mismatch Repair Protein Expression in 101 Primary Melanomas
 Percentage of Positive Cellsa
Protein  0-10 11-20 21-30 31-40 41-50 51-60 61-70 71-80 81-90 91-100 NE
MSH2 3 (3.0) 4 (4.0) 1 (1.0) 7 (7.1) 4 (4.0) 5 (5.1) 8 (8.1) 29 (29.3) 22 (22.2) 16 (16.2) 2
MSH6 43 (44.3) 18 (18.5) 11 (11.3) 9 (9.3) 6 (6.2) 6 (6.2) 2 (2.1) 2 (2.1) 0 0 4
MLH1 0 0 0 0 2 (2.0) 3 (3.0) 7 (6.9) 21 (20.8) 38 (37.6) 30 (29.7) 0 
PMS2 0 0 1 (1.0) 0 1 (1.0) 1 (1.0) 6 (5.9) 15 (14.8) 33 (32.7) 44 (43.6) 0 
a Values indicate the number of samples in the indicated class of expression, with the number in parentheses representing the percentage of the total samples analyzed subtracted 
from the samples that were not evaluable (NE).
❚Table 3❚
Association Between Demographic and Clinicopathologic Characteristics and Mismatch Repair Protein Expression in Primary Melanomasa
 MSH2 (n = 99)  MSH6 (n = 97)  MLH1 (n = 101)  PMS2 (n = 101)
 
Characteristic
Low,b  
No. (%)
High,b 
No. (%)
 
P Valuec
Low,d  
No. (%)
High,d 
No. (%)
 
P Valuec
Low,b  
No. (%)
High,b 
No. (%)
 
P Valuec
Low,b  
No. (%)
High,b 
No. (%)
P  
Valuec
Sex
   Male 37 (60.7) 21 (55.3) 32 (52.5) 24 (66.7) 19 (57.6) 39 (57.4) 16 (66.7) 42 (54.6)
   Female 24 (39.3) 17 (44.7) .60 29 (47.5) 12 (33.3) .17 14 (42.4) 29 (42.6) .98 8 (33.3) 35 (45.4) .29
Age, y
   ≤49 27 (44.2) 12 (31.6) 26 (42.6) 11 (30.6) 17 (51.5) 22 (32.4) 12 (50.0) 27 (35.0)
   50-64 22 (36.1) 10 (26.3) 19 (31.2) 13 (36.1) 6 (18.2) 27 (39.7) 9 (37.5) 24 (31.2)
   ≥65 12 (19.7) 16 (42.1) .06 16 (26.2) 12 (33.3) .49 10 (30.3) 19 (27.9) .07 3 (12.5) 26 (33.8) .13
Breslow 
thickness, mm
   ≤1.00 21 (34.4) 10 (26.3) 24 (39.4) 7 (19.4) 14 (42.4) 19 (27.9) 10 (41.7) 23 (29.9)
   1.01-2.00 14 (23.0) 10 (26.3) 18 (29.5) 6 (16.7) 7 (21.2) 17 (25.0) 5 (20.8) 19 (24.7)
   2.01-4.00 12 (19.6) 8 (21.1) 8 (13.1) 12 (33.3) 5 (15.2) 15 (22.1) 3 (12.5) 17 (22.0)
   >4.00 14 (23.0) 10 (26.3) .88 11 (18.0) 11 (30.6) .02 7 (21.2) 17 (25.0) .56 6 (25.0) 18 (23.4) .64
Anatomical site
   Head/neck 7 (11.5) 6 (15.8) 9 (14.8) 4 (11.0) 7 (21.2) 6 (8.8) 5 (20.8) 8 (10.4)
   Trunk 27 (44.3) 10 (26.2) 24 (39.3) 11 (30.6) 13 (39.4) 24 (35.3) 10 (41.7) 27 (35.0)
   Upper limb 11 (18.0) 11 (29.0) 11 (18.0) 11 (30.6) 7 (21.2) 15 (22.1) 2 (8.3) 20 (26.0)
   Lower limb 16 (26.2) 11 (29.0) .29 17 (27.9) 10 (27.8) .53 6 (18.2) 23 (33.8) .20 7 (29.2) 22 (28.6) .20
Histologic type
   Superficial 
   spreading
40 (65.6) 20 (52.6) 41 (67.2) 18 (50.0) 24 (72.7) 38 (55.9) 17 (70.8) 45 (58.4)
   Nodular 21 (34.4) 18 (47.4) .20 20 (32.8) 18 (50.0) .09 9 (27.3) 30 (44.1) .10 7 (29.2) 32 (41.6) .34
Ulceration
   Absent 54 (88.5) 31 (81.6) 57 (93.4) 28 (77.8) 29 (87.9) 58 (85.3) 19 (79.2) 68 (88.3)
   Present 7 (11.5) 7 (18.4) .34 4 (6.6) 8 (22.2) .05 4 (12.1) 10 (14.7) >.99 5 (20.8) 9 (11.7) .31
Regression
   Absent 55 (90.2) 36 (94.7) 58 (95.1) 32 (88.9) 31 (93.9) 62 (91.2) 21 (87.5) 72 (93.5)
   Present 6 (9.8) 2 (5.3) .71 3 (4.9) 4 (11.1) .42 2 (6.1) 6 (8.8) >.99 3 (12.5) 5 (6.5) .39
Mitoses/mm2
    <1 27 (45.0) 13 (34.2) 32 (52.5) 8 (22.2) 16 (48.5) 26 (38.8) 10 (43.5) 32 (41.6)
    ≥1 33 (55.0) 25 (65.8) .29 29 (47.5) 28 (77.8) .003 17 (51.5) 41 (61.2) .36 13 (56.5) 45 (58.4) .87
Growth phase
   Radial 6 (9.8) 1 (2.6) 7 (11.5) 1 (2.8) 3 (9.1) 6 (8.8) 4 (16.7) 5 (6.5)
   Vertical 55 (90.2) 37 (97.4) .25 54 (88.5) 35 (97.2) .25 30 (90.9) 62 (91.2) >.99 20 (83.3) 72 (93.5) .21
AJCC clinical 
stage
   I 35 (58.3) 20 (52.6) 42 (68.9) 13 (37.1) 21 (63.6) 36 (53.7) 15 (62.5) 42 (55.3)
   II-III 25 (41.7) 18 (47.4) .58 19 (31.1) 22 (62.9) .003 12 (36.4) 31 (46.3) .35 9 (37.5) 34 (44.7) .53
AJCC, American Joint Committee on Cancer.
a Totals may differ because of missing values.
b Low: positive tumor cells 80% or less; high: positive tumor cells more than 80%.
c Pearson χ2 test or Fisher exact test, where appropriate.
d Low: positive tumor cells 20% or less; high: positive tumor cells more than 20%.
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lower in patients with H-MSH6 melanomas compared with 
patients with L-MSH6 tumors (67.9% vs 88.5%, P = .007). 
Patients whose primary melanoma was classified as H-MSH6 
had a fourfold increased RR of mortality (RR, 4.39; 95% 
confidence interval [CI], 1.35-14.30). Kaplan-Meier survival 
curves for patients with H-MSH6 or L-MSH6 melanoma are 
in patients with stage I disease (survival 59.5% vs 95.7%, 
P < .001). No statistically significant difference in survival 
was found for patient sex and age, tumor location, ulceration, 
regression, and growth phase.
❚Table 5❚ shows MMR protein expression, 10-year 
MS, and crude relative risk (RR). MS was significantly 
❚Table 5❚
Mismatch Repair Protein Expression, 10-Year Melanoma Survival, and Crude Relative Risk of Melanoma Mortality
 Survival
Protein Expression Patients (n = 77),a No. (%) Survivors, No. % P Valueb RR (95% CI)c P Value
MSH2     
   Low (0-80) 47 (62.7) 40 83.2  1 [Reference] 
   High (81-100) 28 (37.3) 22 78.4 .44 1.53 (0.51-4.56) .45
MSH6     
   Low (0-20) 47 (62.7) 43 88.5  1 [Reference] 
   High (21-100) 28 (37.3) 19 67.9 .007 4.39 (1.35-14.30) .01
MLH1     
   Low (0-80) 22 (28.6) 19 86.4  1 [Reference] 
   High (81-100) 55 (71.4) 5 79.4 .58 1.43 (0.39-5.20) .59
PMS2     
   Low (0-80) 16 (20.8) 13 81.3  1 [Reference] 
   High (81-100) 61 (79.2) 51 81.3 .83 0.87 (0.24-3.16) .83
a Totals may differ from 77 because of missing values.
b Log rank test.
c Crude relative risk (RR) and 95% confidence interval (CI), evaluated by the Cox proportional hazards model.
❚Table 4❚
Demographic and Clinicopathologic Data and 10-Year Melanoma Survival
 Survival
Characteristic Patients (n = 77), No. (%) Survivors, No. % P Valuea
Sex   
   Male 44 (57.1) 37 83.9 
   Female 33 (42.9) 27 79.7 .77
Age, y   
   ≤49 26 (33.8) 23 86.5 
   50-64 26 (33.8) 19 73.1 
   ≥65 25 (32.4) 22 87.1 .29
Breslow thickness, mm   
   0.3-4 57 (74.0) 53 91.4 
   >4 20 (26.0) 11 50.5 <.0001
Anatomical site   
   Head/neck 10 (13.0) 9 90.0 
   Trunk 29 (37.7) 26 89.4 
   Upper limb 16 (20.8) 13 81.3 
   Lower limb 22 (28.6) 16 68.2 .35
Histologic type   
   Superficial spreading 45 (58.4) 41 89.4 
   Nodular 32 (41.6) 23 70.2 .01
Ulceration   
   Absent 68 (88.3) 58 83.5 
   Present 9 (11.7) 6 66.7 .11
Regression   
   Absent 71 (92.2) 58 80.0 
   Present 6 (7.8) 6 100.0 .27
Mitoses/mm2   
   <1 37 (48.0) 37 100.0 
   ≥1 40 (52.0) 27  63.3 <.001
Growth phase   
   Radial 8 (10.4) 8 100.0 
   Vertical 69 (89.6) 56 79.3 .19
AJCC clinical stage   
   I 46 (59.7) 44 95.7 
   II-III 31 (40.3) 20 59.5 <.001
AJCC, American Joint Committee on Cancer.
a Log rank test.
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Discussion
Germline mutations affecting DNA repair genes have been 
clearly associated with a high risk of cancer development.21 On 
the other hand, gene expression profiling of tumor cell lines 
and specimens of different histologic origin has evidenced that 
overexpression of DNA repair genes is frequently associated 
with more aggressive behavior of cancer cells and/or with 
lower patient disease-free or overall survival.22 These findings 
have led to the hypothesis that while genetic instability is 
essential for tumor initiation, it may be deleterious in the 
progression or metastatic process.22
The MMR system is a DNA repair pathway dedicated to 
the correction of replication errors that escape processing by the 
proofreading activity of the replicative DNA polymerase.15,16 
In eukaryotic cells, the key proteins involved in MMR 
are MSH2, MSH6, MLH1, and PMS2.15,16 The protein 
complex MutSa, a heterodimer of MSH2 and MSH6, initially 
recognizes and binds base/base mismatches and insertion/
deletion loops of one to three nucleotides. After this step, the 
heterodimer of MLH1 and PMS2, termed MutLa, interacts 
with the DNA-bound MutSa to initiate the repair process, 
which also requires additional proteins involved in DNA 
metabolism (eg, helicases, exonucleases).15,16 MMR proteins 
are also involved in DNA damage signaling, in the processing 
of modified bases, and can interact with partners involved in 
other pathways of DNA repair.15,16 Mutations in MMR genes 
confer genetic instability and are implicated in hereditary 
nonpolyposis colon cancer.15,16 Notably, Winnepenninckx et 
al8 and Kauffmann et al10 found that both MSH2 and MSH6 
were among the genes overexpressed in primary melanomas 
that had metastasized within 4 years from diagnosis compared 
with those that had not. Elevated levels of MSH2 and MSH6 
mRNA in primary melanomas have also been described 
by Jewell et al12 as being associated with unfavorable 
histopathologic features. Finally, overexpression of MSH6 
occurred in primary melanomas classified by Harbst et 
al13 as “high-grade” melanomas, according to a two-class 
signature constructed through gene expression profiling of 
a large set of tumor specimens. Compared with “low-grade” 
shown in ❚Figure 1❚. No difference in survival was found for 
expression levels of MSH2, MLH1, and PMS2 (Table 5).
Using the Cox proportional hazards model, multivariate 
analyses were performed to assess the independent predictive 
value of MSH6 protein expression among the primary 
melanomas. ❚Table 6❚ shows the estimated RR of melanoma 
death and 95% CIs. The presence of ulceration and high 
mitotic rate were strongly associated (P = .002), as well 
as Breslow thickness and histologic type (P < .0001). To 
avoid multicollinearity, ulceration and mitotic rate were not 
included simultaneously in the multivariate models. After 
controlling for age and sex, Breslow thickness, and ulceration, 
MSH6 expression remained an independent prognostic factor 
for melanoma mortality (RR, 3.76; 95% CI, 1.12-12.70; P 
= .03). Other variables such as anatomical site, regression, 
and growth phase were also considered one at a time in the 
models, but the results did not change.
❚Table 6❚
MSH6 Expression and Melanoma Mortality: Adjusted Relative Risk (RR) and 95% Confidence Intervals (CIs) for High MSH6 
Expression (H-MSH6)
 Melanoma Mortality
Multivariate Model RR (95% CI)a P Value
Model a: H-MSH6, sex, age  4.60 (1.40-15.10) .01
Model b: model a plus Breslow thickness 3.82 (1.15-12.70) .03
Model c: model a plus presence of ulceration 4.23 (1.27-14.10) .02
Model d: model a plus Breslow thickness and ulceration 3.76 (1.12-12.70) .03
a Evaluated by the Cox proportional hazards model.
0.00
0.25
0 2 4
Years
K
ap
la
n-
M
ei
er
 S
ur
vi
va
l F
un
ct
io
n
6 8
L-MSH6
H-MSH6
10
0.50
0.75
1.00
❚Figure 1❚ Melanoma survival in patients with stage I to 
III disease according to MSH6 protein expression in the 
primary tumor. H-MSH6, positive tumor cells more than 20%; 
L-MSH6, positive tumor cells 20% or less. P = .007.
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whereas in primary melanomas, the percentage of tumor cells 
staining positive for proliferation markers has been reported 
to range between 5% and 50%.27,28,31,33 Moreover, in CMNs, 
proliferating nevus cells were located in the junctional 
component28,29,31 or in the mid-dermal portion27,30 of the 
nevus, whereas in primary melanomas, they were evidenced 
also in the deep dermal tumor nests.28,32,33 We can hypothesize 
that in both benign nevi and primary melanomas, MSH6 is 
expressed only in proliferating cells, whereas MSH2, MLH1, 
and PMS2 are also present in resting cells. This hypothesis is 
further supported by the finding that the expression of MSH6 
but not that of MSH2, MLH1, or PMS2 was significantly 
associated with the mitotic rate of primary melanomas.
With respect to the relationship between MMR protein 
expression and clinicopathologic variables, our data show that 
high MSH6 expression in primary melanomas was significantly 
associated with unfavorable histopathologic features—namely, 
tumor thickness of more than 2 mm, ulceration, and number 
of mitoses/mm2 of 1 or more—and with clinical stages II to 
III. Patients with H-MSH6 melanomas showed a lower rate 
of survival (67.9%) compared with patients with L-MSH6 
melanomas (88.5%). In the univariate analysis, patients with 
H-MSH6 melanomas had a risk of death fourfold higher than 
that of patients with L-MSH6 tumors. More important, MSH6 
expression was independent of age and sex, Breslow thickness, 
and ulceration in the prediction of 10-year melanoma mortality 
in the multivariate Cox regression analysis. In the multivariable 
analysis, Breslow thickness remained statistically significant. 
These results confirm, at the protein level, previous data 
from gene expression profiling showing high levels of MSH6 
melanomas, “high-grade” tumors were associated with 
negative clinicopathologic prognostic factors and poorer 
relapse-free survival and overall survival.13 On these bases, 
in the present study we analyzed the expression of MSH2, 
MSH6, MLH1, and PMS2 proteins in CMNs and in a large 
series of primary melanomas, as well as investigated its role 
as a prognostic factor in patients with stage I to III disease.
To our knowledge, only five studies,19,23-26 briefly 
described in ❚Table 7❚, have analyzed the expression of one 
or more MMR proteins in both benign nevi and primary 
melanomas, with some contrasting results. Overall, the results 
of our study, which is the first to evaluate the expression of 
all four key MMR proteins in the same set of benign nevi and 
primary melanomas, support previous findings showing that 
MSH2, MLH1, and PMS2 proteins are expressed in most 
nevus cells and that, with respect to benign nevi, a subset of 
primary melanomas displays reduced immunostaining for one 
or more of these MMR proteins. Differently from Hussein et 
al,19 we detected an extremely low MSH6 immunoreactivity 
in benign nevi and increased MSH6 expression in a subset of 
primary melanomas. Notably, none of the CMNs displayed 
MSH6 immunoreactivity in the dermal portion of the lesion, 
whereas dermal expression of MSH6 was always present in 
MSH6-positive primary melanomas. The expression pattern 
of MSH6 in benign nevi and primary melanomas partially 
resembles that reported by previous studies for several 
proliferation markers, including Ki-67, topoisomerase II-a, 
and proliferating cell nuclear antigen. In benign nevi, the 
percentage of melanocytes expressing these markers has 
been shown to be very low, ranging between 0% and 4%,27-32 
❚Table 7❚
Studies That Have Analyzed the Expression of One or More MMR Proteins in Both Benign Nevi and Primary Melanomas
Author Samplesa Proteinb Protein Expression in BNs Protein Expression in PMs
Korabiowska et al23 51 BNs and  
78 PMs
MSH2, MLH1,  
and PMS2
The three proteins were expressed 
in most samples, even though there 
were appreciable differences in the 
percentage of positive cells.
Only 37% of the samples displayed 
positive immunostaining for all the 
proteins.
Hussein et al19 19 BNs and  
9 PMs
MSH2, MSH6,  
and MLH1
The three proteins were highly 
expressed in all samples.
The percentage of cells staining 
positive for any of the proteins was 
reduced compared with BNs.
Rass et al24 8 BNs and  
15 PMs
MSH2 The protein was absent (one case) or 
present in a few scattered nevus cells.
All samples displayed positive 
immunostaining for the protein 
in almost the entire tumor cell 
population.
Alonso et al25 10 BNs and  
94 PMs
MSH2 and MLH1 Almost all samples showed MSH2- 
and MLH1-positive staining in more 
than 70% and 50% of the nevus cells, 
respectively.
A few samples showed reduced 
expression of the two proteins 
compared with BNs.
Song et al26 53 BNs and  
312 PMs
MSH2 The protein was expressed in all 
samples with different histoscore 
values.
The protein was expressed in all 
samples with different histoscore 
values. The median value of the MSH2 
histoscore did not differ significantly 
from that of BNs.
a Number of benign nevi (BNs) and primary melanomas (PMs) examined.
b The expression of the indicated mismatch repair (MMR) proteins was evaluated by immunohistochemistry.
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functional MMR system, but emerging evidence also supports 
a key role for this protein in MMR-dependent DNA damage 
response and in the interaction between MMR and other DNA 
repair pathways within the cells.37 For instance, MSH6 has 
been reported to interact with Ku70 and to promote DNA 
double-strand break repair by nonhomologous end joining.37 
It also associates with the Bloom syndrome helicase, which 
plays an important role in the repair of DNA double-strand 
breaks by homologous recombination.37 MSH6 expression 
in proliferating cells could therefore confer protection against 
different types of DNA damage, promoting survival and, 
hence, a successful metastatic spreading. Future studies 
aimed at a deep molecular characterization (eg, whole-exome 
sequencing, gene expression profiling) of primary melano-
mas with “high” or “low” expression of MSH6 protein might 
disclose the key molecular pathways underlying the higher 
aggressiveness of the tumors with the H-MSH6 phenotype. 
It is worth noting that although tumor cells expressing a 
functional MMR are more protected against a variety of DNA 
damages, they can be susceptible to the cytotoxic effects of 
chemotherapeutic methylating agents able to form adducts at 
the O6 position of guanine (ie, dacarbazine, temozolomide). 
O6-methylguanine (O6-MeG) in DNA can be repaired by the 
enzyme O6-methylguanine-DNA methyltransferase (MGMT), 
which is expressed at variable levels in tumor cells.38-40 In the 
absence of repair, however, O6-MeG frequently mispairs with 
thymine during DNA duplication. O6-MeG:T mismatches can 
be then recognized by the MMR system, which activates a 
signaling cascade resulting in cell cycle arrest at the G2 phase 
of the second cell doubling event, which is followed by apop-
tosis, mitotic catastrophe, or a senescence-like state.41-46 In 
MMR-proficient cells, sensitivity to O6-guanine-methylating 
agent is strictly dependent on the level of MGMT, whereas 
cells with a defective MMR are highly resistant to these 
agents, regardless of their MGMT activity.
In conclusion, our study provides further insight into 
the expression pattern of MSH2, MSH6, MLH1, and PMS2 
proteins in benign nevi and primary melanomas and suggests 
that the level of MSH6 protein expression can provide useful 
prognostic information beyond that provided by routine 
clinical and histologic factors. Additional studies by other 
investigators are warranted to definitely ascertain whether 
MSH6 protein expression can be used as an additional 
independent prognostic indicator in primary melanoma to 
identify patients at higher risk for death due to the disease, 
who would then be candidates for adjuvant therapy.
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mRNA in more aggressive primary melanomas.8,10,12,13 In 
our study, neither MSH2 expression nor that of MLH1 and 
PMS2 was significantly associated with any clinicopathologic 
parameter or patient 10-year MS. In a recent investigation by 
Meyer et al,34 MSH2 and MLH1, but not MSH6 and PMS2, 
were included in a panel of 70 proteins whose expression was 
evaluated by immunohistochemistry in the primary melanoma 
of 364 patients to identify a multimarker signature predictive of 
clinical outcome. In this investigation, high MLH1 but not high 
MSH2 expression was associated with a high risk of melanoma 
mortality in the univariate analysis. Song et al26 reported that 
patients with primary melanomas displaying high MSH2 
protein levels did not show lower survival compared with 
patients whose tumors had low MSH2 expression. Regarding 
MSH2 expression, our data are consistent with these previous 
findings and further confirm that even though overexpression 
of MSH2 mRNA has been detected in primary melanomas 
with unfavorable histopathologic features and/or poor clinical 
outcome,8,10,12 the expression of MSH2 protein is not a 
prognostic factor for melanoma mortality. On the other hand, 
it cannot be excluded that we did not evidence an association 
between MLH1 expression and melanoma mortality as a result 
of the lower number of patients included in our study with 
respect to that considered by Meyer and colleagues.34
As discussed above, the staining pattern of MSH6 in 
benign nevi and primary melanomas supports the hypothesis 
that this protein is expressed in proliferating but not resting 
nevus or tumor cells. Elevated mitotic rate (histologically 
defined as mitoses/mm2 ≥1) has been demonstrated to be 
an important independent adverse predictor of survival in 
melanoma, and in the seventh edition of the AJCC Melanoma 
Staging and Classification, it has replaced the Clark level of 
invasion as the primary criterion for defining the T1b subcat-
egory.3 High expression of the Ki-67 proliferation markers 
in primary melanoma also has been clearly associated with 
poor clinical outcome (reviewed in Gould Rothberg et al35 
and Moore et al36). The prognostic value of high MSH6 
expression in primary melanomas can therefore be in part 
dependent on its association with proliferation. However, for 
metastatic spreading, which ultimately determines patient 
outcome, tumor cells must be able not only to proliferate but 
also to leave the original site, enter the bloodstream, reach a 
distant organ, extravasate, and grow. Accordingly, in several 
types of malignancies, a large number of genes involved in 
different biological processes beside proliferation appear to be 
differentially expressed between tumors that had developed 
metastasis and tumors that had not.6,7 Many DNA repair genes 
are among those genes frequently overexpressed in cancer 
that are going to metastasize, and it has been suggested that 
this ensures highly proliferating cells protection from DNA 
damage, promoting invasiveness and survival in unfavorable 
environments.22 The MSH6 protein not only is required for a 
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